—
C+
C+ The full Closelook — membership. Open the C+ overview

10X Genomics Inc (TXG) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — 10X Genomics Inc

TXG in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
10x Genomics designs and sells instruments, consumables and software used to study individual cells and their spatial position within tissue. Its Chromium platform separates single cells for genetic analysis, while Visium and Xenium map gene activity back onto a tissue slide. Customers are academic, government and biopharmaceutical laboratories that use these tools for research rather than clinical diagnosis. The company is based in Pleasanton, California, and listed since 2019.
Where it sits in the stack
10x Genomics sits in the life-sciences tools and diagnostics corner of the healthcare sector our universe tracks, outside any Closelook index sleeve for now. It supplies the instruments and reagents that biopharmaceutical and academic labs consume for single-cell and spatial research, work that sits upstream of drug discovery rather than inside the AI compute build-out.
Who it is priced against
The instrument-and-consumables model invites comparison with other genomics tool makers such as Illumina and Pacific Biosciences, though none appears alongside it as a formal peer set here.
Why Closelook tracks it
It holds a seat in the Russell 1000 and has been named once in our diary, in a Midday 10 note listing large-cap stocks making new 52-week highs; it does not yet carry a Closelook score.
What the diary watches
Whether adoption of spatial and single-cell tools broadens beyond research labs into applied or clinical settings, which would change how the diary reads its growth.

10X Genomics Inc (TXG) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for TXG, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Medical Devices · United States · 8 names with week and year-to-date

Peer group

Medical Devices · United States

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against TXG on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is 10X Genomics Inc (TXG)?

10X Genomics Inc trades as TXG on the US exchange (United States) in the Closelook research universe, as of the registry build of 2026-09-18.

Is TXG in a Closelook index?

Not currently — 10X Genomics Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does TXG trade against its moving averages?

Uptrend stack intact: Trades +37.4% vs the 50-day and +148% vs the 200-day average, 3.7% below the 52-week high and +589.7% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does 10X Genomics Inc do?

10x Genomics designs and sells instruments, consumables and software used to study individual cells and their spatial position within tissue. Its Chromium platform separates single cells for genetic analysis, while Visium and Xenium map gene activity back onto a tissue slide. Customers are academic, government and biopharmaceutical laboratories that use these tools for research rather than clinical diagnosis. The instrument-and-consumables model invites comparison with other genomics tool makers such as Illumina and Pacific Biosciences, though none appears alongside it as a formal peer set here.

Where does 10X Genomics Inc sit in the AI build-out?

10x Genomics sits in the life-sciences tools and diagnostics corner of the healthcare sector our universe tracks, outside any Closelook index sleeve for now. It supplies the instruments and reagents that biopharmaceutical and academic labs consume for single-cell and spatial research, work that sits upstream of drug discovery rather than inside the AI compute build-out. It holds a seat in the Russell 1000 and has been named once in our diary, in a Midday 10 note listing large-cap stocks making new 52-week highs; it does not yet carry a Closelook score.

Where has Closelook written about 10X Genomics Inc?

10X Genomics Inc appears in 1 Closelook piece, most recently Midday 10: A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000 (2026-08-21). What Closelook said most recently: Barchart's large-cap 52-week new-high list, as of 11:59 CDT, carries 31 names and reads like the ex-tech thesis printed as breadth: twelve are health care, biotech or pharma — ARGX, BDX, BIO, CORT, HALO, MRK, REGN, RVTY, THC, TVTX, TXG… (Midday 10, 2026-08-21). The "Mentioned on Closelook" block on this page lists the long reads, the reference entries and the dailies that name it.

What does this page show?

A live price chart with SMA overlays and drawing tools for TXG, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Mentioned on Closelook 1 piece · newest: Midday 10, “A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000” (2026-08-21)

Mentioned on Closelook

Where TXG appears in the diary — 1 piece, newest first. Every link is our own writing.

Dailies

Related in the Closelook universe

then Medical Devices. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.